The Effect of Inhaled Ozone Therapy in Two-Hit Rat Model of Lipopolysaccharides-Induced Acute Lung Injury and Bleomycin-Induced Pulmonary Fibrosis

ArticleAçık Erişim

Özet

Considering the limited treatment options for acute lung injury (ALI) and pulmonary fibrosis (PF), ozone treatment may be promising as a new immunological agent with its ability to modulate cytokines and interferons. We aimed to investigate the effects of inhaled ozone therapy on both ALI and PF in rat models. A total of 48 albino Wistar male rats were included in the study. Lipopolysaccharide (LPS) was used to induce the ALI model, and bleomycin was used for the PF model. The effects of inhaled ozone (O3) were investigated using the ELISA method. Hematoxylin&eosin staining, Masson’s trichrome staining, and immunohistochemical methods were used for histopathological evaluation. The Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), and Nuclear Factor kappa B subunit p65 (NF-κB p65) levels in the ALI + 0.08 ppm O3, ALI + 0.12 ppm O3, PF + 0.08 ppm O3, and PF + 0.12 ppm O3 groups statistically decreased to the same extent and approached the levels of control animals. It was observed that IL-1β, IL-6, TNF-α, and NF-κB p65 levels in lung tissues were significantly and dose-dependently decreased compared to the untreated PF and ALI groups, respectively. While fibrosis was severe in the PF + 0.08 ppm O3 group, it decreased to more moderate levels in the PF + 0.12 ppm O3 group. The cytokine levels confirmed that inhaled ozone protected the lungs from both ALI and the development of PF. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10757Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s10930-024-10247-4Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCelik, Mine
dc.contributor.authorKoca, Mehmet
dc.contributor.authorHalici, Zekai
dc.contributor.authorTavaci, Taha
dc.contributor.authorHalici, Hamza
dc.contributor.authorOzkaraca, Mustafa
dc.contributor.authorKarakoy, Zeynep
dc.contributor.authorBayraktutan, Zafer
dc.date.accessioned2026-10-18T20:25:54.194255663Z
dc.date.available2026-10-18T20:25:54.194255663Z
dc.date.issued2025
dc.description.abstractConsidering the limited treatment options for acute lung injury (ALI) and pulmonary fibrosis (PF), ozone treatment may be promising as a new immunological agent with its ability to modulate cytokines and interferons. We aimed to investigate the effects of inhaled ozone therapy on both ALI and PF in rat models. A total of 48 albino Wistar male rats were included in the study. Lipopolysaccharide (LPS) was used to induce the ALI model, and bleomycin was used for the PF model. The effects of inhaled ozone (O3) were investigated using the ELISA method. Hematoxylin&eosin staining, Masson’s trichrome staining, and immunohistochemical methods were used for histopathological evaluation. The Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), and Nuclear Factor kappa B subunit p65 (NF-κB p65) levels in the ALI + 0.08 ppm O3, ALI + 0.12 ppm O3, PF + 0.08 ppm O3, and PF + 0.12 ppm O3 groups statistically decreased to the same extent and approached the levels of control animals. It was observed that IL-1β, IL-6, TNF-α, and NF-κB p65 levels in lung tissues were significantly and dose-dependently decreased compared to the untreated PF and ALI groups, respectively. While fibrosis was severe in the PF + 0.08 ppm O3 group, it decreased to more moderate levels in the PF + 0.12 ppm O3 group. The cytokine levels confirmed that inhaled ozone protected the lungs from both ALI and the development of PF. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
dc.description.sponsorshipThis study was supported by Ataturk University Clinical Research Development and Design Center. This study received no financial support.
dc.identifier.doi10.1007/s10930-024-10247-4
dc.identifier.eissn1875-8355
dc.identifier.endpage339
dc.identifier.issn1572-3887
dc.identifier.issue3
dc.identifier.pmid39920533
dc.identifier.scopus2-s2.0-85217698906
dc.identifier.startpage325
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10757
dc.identifier.volume44
dc.identifier.wosWOS:001415666200001
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofProtein Journal
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute lung Injury
dc.subjectCytokines
dc.subjectInhaled Ozone Therapy
dc.subjectOzone
dc.subjectPulmonary Fibrosis
dc.subjectAdministration, Inhalation
dc.subjectAnimals
dc.subjectBleomycin
dc.subjectDisease Models, Animal
dc.subjectLipopolysaccharides
dc.subjectLung
dc.subjectMale
dc.subjectRats
dc.subjectRats, Wistar
dc.subjecteosin
dc.subjecthematoxylin
dc.subjectinterleukin 1beta
dc.subjectinterleukin 6
dc.subjecttranscription factor RelA
dc.subjecttumor necrosis factor
dc.subjectcytokine
dc.subjectlipopolysaccharide
dc.subjectalbino rat
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectbleomycin-induced pulmonary fibrosis
dc.subjectcontrolled study
dc.titleThe Effect of Inhaled Ozone Therapy in Two-Hit Rat Model of Lipopolysaccharides-Induced Acute Lung Injury and Bleomycin-Induced Pulmonary Fibrosis
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus3
rdl.citation.wos4
rdl.departmentDepartment of Pharmacology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)